Halozyme Therapeutics | HALO - 净收入



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 14.48B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


净收入 更改 日
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 2.38B 556M 2026-06
Baxter International USD 126M 141M 2026-06
Cara Therapeutics USD -6.8M 1.28M 2026-03
Cytokinetics USD -198.76M 7.27M 2026-06
DBV Technologies USD -47.6M 2.77M 2026-03
Eli Lilly USD 7.1B 301M 2026-06
Halozyme Therapeutics USD 229.91M 79.86M 2026-06
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
MannKind USD -16.62M 671K 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Pfizer USD -248M 2.94B 2026-06
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
United Therapeutics USD 333M 58.1M 2026-06
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12